Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3475 + RT in Advanced Solid Tumors
NCT02318771Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2015
- Primary completion
- Jun 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pembrolizumab in head and neck cancer (HNC), renal cell carcinoma (RCC), melanoma and 1 more (4 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Change in PD-L1 levels. Started Feb 2015; status: completed.
02
Drugs
03
Conditions
head and neck cancer (HNC)renal cell carcinoma (RCC)melanomalung cancer
Beyond the preview
Go deeper on NCT02318771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02318771.